COCP · Cocrystal Pharma Inc
United States · RS rating 54 · As of 2026-11-03
| Price | 1.07 USD |
|---|---|
| 1-day change | +0.9% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 47 / 76 / 49 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 30 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -35.3% |
| Sales growth Q/Q | -53.3% |
| Distance from 52-week high | +31.9% |
| Market cap (USD) | $19.4M |